Ocugen (OCGN) Valuation Check As Social Media Speculation Lifts Interest In Gene Therapy Prospects [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
elevated volatility, putting this small cap biotech back in focus for risk tolerant investors. See our latest analysis for Ocugen. At a share price of US$1.50, Ocugen's recent 22% 1 month share price return and 8.7% year to date share price return contrast with a 12.3% 3 month share price decline, while the 1 year total shareholder return of 90.7% suggests momentum has recently been building rather than fading. If Ocugen's swings have caught your attention, this could be a good moment to scan other healthcare names and see what stands out using our healthcare stocks Ocugen's shares trade at US$1.50 compared with an analyst price target of US$9.00 and an intrinsic value estimate that implies a very large discount. This raises the question: is this a genuine opportunity, or is the market already pricing in future growth? With Ocugen last closing at US$1.50 against a most-followed fair value of about US$9.00, the narrative is anchoring to a very different price. Ocugen is pro
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]Yahoo! Finance
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial DataGlobeNewswire
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene TherapyGlobeNewswire
- Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 8/1/25 - In-Line
OCGN
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 12/18/25 - Form 8-K
- OCGN's page on the SEC website